Prof Thomas Tursz talks to ecancer about the movement towards personalised medicine and the current problems in clinical trials in Berlin, May 2012.

The movement towards personalised medicine indicates a need for reorganisation in clinical trials. In clinical trials, 97% of patients in Europe are not in a trial. These patients are at a disadvantage because the process of joining a clinical trial involves a much more thorough analysis of their disease. Data shows that patients in clinical trials have better outcomes than those not in them.